Peer-reviewed veterinary case report
VDC-1101 treatment results for dogs with skin T-cell lymphoma
By Morges, M A et al.·Published in Journal of veterinary internal medicine·2014·Colorado State University, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma.
- Species:
- dog
Plain-English summary
A group of 12 dogs with a rare skin cancer called cutaneous T-cell lymphoma (CTCL) received a new treatment called VDC-1101, given through an IV infusion every three weeks. The treatment showed promise, with one dog achieving complete remission and four others showing partial improvement. Overall, 45% of the dogs responded positively to the treatment, and some had stable disease for over a year. While there were some mild side effects, including skin issues in a few dogs, the treatment was generally well-tolerated. This new option could be beneficial for dogs suffering from this challenging condition.
People also search for: dog skin cancer treatment · cutaneous T-cell lymphoma in dogs · VDC-1101 for canine lymphoma
Abstract
BACKGROUND: Canine cutaneous T-cell lymphoma (CTCL) is an uncommon disease for which efficacious therapies are lacking. The novel anticancer nucleotide prodrug VDC-1101 (formerly known as GS-9219) has shown efficacy in dogs with multicentric lymphoma. One of the observed adverse effects with this drug was a skin change characterized by hair loss, erythema, and pruritus, implying delivery of VDC-1101 to the skin. HYPOTHESIS/OBJECTIVES: The primary study objective was to identify the objective response rate (ORR) to VDC-1101 in canine CTCL; secondary objectives included characterization of progression-free survival (PFS) and adverse events (AEs). ANIMALS: Twelve dogs with chemotherapy-naïve or relapsed, histologically and immunohistochemically confirmed CTCL. METHODS: Dogs received VDC-1101 as a 30-minute IV infusion once every 21 days. Prednisone (1 mg/kg PO q48h) was administered concurrently. RESULTS: In 11 evaluable patients, responses included 1 complete response (CR), 4 partial responses (PR), 2 stable disease (SD), and 4 progressive disease for an ORR of 45% and biologic response rate (CR/PR/SD) of 64%. The median PFS was 37.5 days (26 to >399 days), which includes 1 durable and ongoing CR (>1 year). Gastrointestinal and hematologic AEs were mild; no dogs developed grade 3 or 4 AEs. Three dogs developed dermatopathies and 1 of these dogs was removed from the study as a result of this AE. CONCLUSIONS AND CLINICAL IMPORTANCE: VDC-1101 has activity against canine CTCL and could provide another treatment option in a disease process with a poor prognosis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25274443/